Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
(TSE:4565.T), HTL0039732 (also known as NXE0039732) is Nxera's novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732, was found to be well-tolerated, confirmed target engagement and demonstrated encouraging early efficacy in two distinct tumor types when administered in combination use with atezolizumab Phase 1 […]